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Abstract
Background: Vascular Endothelial Growth Factors (VEGFs) and their receptors (VEGF-Rs) are important regulators
for angiogenesis and lymphangiogenesis. VEGFs and VEGF-Rs are not only expressed on endothelial cells but also
on various subtypes of solid tumors and leukemias contributing to the growth of the malignant cells. This study
was performed to examine whether VEGF-R2 (KDR) and VEGF-R3 (FLT4) are regulated by DNA methylation.
Methods: Real-time (RT) PCR analysis was performed to quantify KDR and FLT4 expression in some ninety
leukemia/lymphoma cell lines, human umbilical vein endothelial cells (HUVECs) and dermal microvascular
endothelial cells (HDMECs). Western blot analyses and flow cytometric analyses confirmed results at the protein
level. After bisulfite conversion of DNA we determined the methylation status of KDR and FLT4 by DNA sequencing
and by methylation specific PCR (MSP). Western blot analyses were performed to examine the effect of VEGF-C on
p42/44 MAPK activation.
Results: Expression of KDR and FLT4 was observed in cell lines from various leukemic entities, but not in
lymphoma cell lines: 16% (10/62) of the leukemia cell lines expressed KDR, 42% (27/65) were FLT4 positive. None of
thirty cell lines representing six lymphoma subtypes showed more than marginal expression of KDR or FLT4.
Western blot analyses confirmed KDR and FLT4 protein expression in HDMECs, HUVECs and in cell lines with high
VEGF-R mRNA levels. Mature VEGF-C induced p42/44 MAPK activation in the KDR
- /FLT4
+ cell line OCI-AML1
verifying the model character of this cell line for VEGF-C signal transduction studies. Bisulfite sequencing and MSP
revealed that GpG islands in the promoter regions of KDR and FLT4 were unmethylated in HUVECs, HDMECs and
KDR
+ and FLT4
+ cell lines, whereas methylated cell lines did not express these genes. In hypermethylated cell lines,
KDR and FLT4 were re-inducible by treatment with the DNA demethylating agent 5-Aza-2’deoxycytidine, confirming
epigenetic regulation of both genes.
Conclusions: Our data show that VEGF-Rs KDR and FLT4 are silenced by DNA methylation. However, if the
promoters are unmethylated, other factors (e.g. transactivation factors) determine the extent of KDR and FLT4
expression.
Background
Vascular endothelial growth factors (VEGFs) and their
corresponding receptors (VEGF-Rs) are important regu-
lators of angiogenesis and lymphangiogensis. VEGF-A
binds VEGF-R1 (FLT1) and VEGF-R2 (KDR). Both tyro-
sine kinase receptors are expressed on blood vessel
endothelial cells. VEGF-C and VEGF-D bind to VEGF-
R3 (FLT4) and the fully processed, mature forms also to
KDR. FLT4 is primarily expressed on cells of the
lymphatic endothelium [1]. VEGFs and VEGF-Rs are
important for vessel formation in healthy individuals,
but also for tumor angiogenesis [2]. Moreover, the
VEGF-Rs are not only expressed on endothelia, but also
on different types of solid tumor cells and on leukemic
cells [3-11]. The interaction of receptors with their
ligands mediates survival and can lead to proliferation of
the malignant cells [2,12].
Even twenty years after their discovery, little is known
about the regulation of the three VEGF-Rs. On the tran-
scriptional level, NF-Ba n dt h eN F - Bt a r g e tProx1
have been described as activators of FLT4 in lymphatic
endothelial cells [13]. Epigenetic mechanisms contribute
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tigated in great detail [14,15].
We set out to test whether DNA methylation is also
responsible for the silencing of FLT4.W ed e t e r m i n e d
the methylation status of KDR and FLT4 in human
umbilical vein endothelial cells (HUVECs), dermal
microvascular endothelial cells (HDMECs) and in a
large panel of leukemia and lymphoma cell lines. Con-
firming that expression of KDR and FLT4 is epigeneti-
cally regulated, we observed an inverse correlation
between promoter methylation and receptor expression.
Furthermore, the demethylating agent 5-Aza-2’deoxycy-
tidine (5-Aza-dC) induced expression of KDR and FLT4
in methylated, but not in unmethylated cell lines.
Methods
Cell lines and primary cell cultures
The cell lines in this study were taken from the stock of
the cell bank (DSMZ–German Collection of Microor-
ganisms and Cell Cultures; http://www.dsmz.de).
Detailed references and cultivation protocols have been
d e s c r i b e dp r e v i o u s l y[ 1 6 ] .P r i m a r yH D M E C sw e r ep u r -
chased from Clonetics/Lonza (Verviers, Belgium). Pri-
mary HUVECS (pooled) were purchased from
PromoCell (Heidelberg, Germany). HDMECs and
HUVECs were cultured in endothelial cell growth med-
ium MV (Promo Cell).
CpG island search
CpG island search was done with Methyl Primer Express
v1.0 software and EMBOSS CpG plot (http://www.ebi.ac.
uk/Tools/emboss/cpgplot/index.html). The criteria for an
island were: GC content > 50%; CpG observed versus
CpG expected ratio > 0.6, length > 100 bp.
Methylation-specific polymerase chain reaction (MSP)
Bisulfite conversion of DNA was performed as described
by the supplier (EpitTect Bisulfite Kit, Qiagen, Hilden,
Germany). For detecting FLT4 and KDR promoter
methylation, we performed nested PCR with first round
primers (FLT4 BSP fwd 5’-AAA TAT TTG GGG GAG
TTT TAA A-3’, FLT4 BSP rev 5’-CCC AAT CTC AAA
AAT AAA CAA A-3’; KDR BSP fwd 5’-AAG TTG TTG
TTT TGG GAT GTT T-3’, KDR BSP rev 5’-AAA TAA
ACT CCT TAC CCA CAA A-3’)a m p l i f y i n gc o n v e r t e d
DNA independently of the methylation status (bisulfite-
specific PCR or BSP; annealing temp.: 54.9°C for FLT4
BSP, 54.7°C for KDR BSP, 35 cycles), and second round
primers for M- and U-PCR specifically recognizing the
methylated or unmethylated versions of the promoter
(FLT4 Mf w d5 ’-GTC GGT TAT TTC GGG TGT TTC
-3’, FLT4 Mr e v5 ’-AAT ATC GAC GAA CAA TAT
CGA CG-3’, FLT4 U fwd 5’-GGG TTG GTT ATT TTG
GGT GTT TT-3’, FLT4 Ur e v5 ’-ACA CAA TAT CAA
CAA ACA ATA TCA ACA-3’, KDR Mf w d5 ’-CGT
TTT CGC GTT TTA GAG TTT C-3’, KDR Mr e v5 ’-
GCG CAA ATA ATA CCC GAC G-3’, KDR Uf w d5 ’-
TTT TGT TTT TGT GTT TTA GAG TTT T-3’, KDR
Ur e v5 ’-ACA CAC AAA TAA TAC CCA ACA-3’).
PCR products of the initial BSP were diluted 1:100 to
1:4.000 for subsequent M- and U-PCR. Annealing tem-
perature was 61.2°C for FLT4 M- and U-PCR, 58°C for
KDR M- and U-PCR with 30 cycles each. Epitect PCR
Control DNA (Qiagen) was used as control for methy-
lated and unmethylated templates.
Bisulfite sequencing
To confirm the methylation status of the FLT4 and KDR
promoters, genomic DNA was bisulfite converted
according to the manufacturer’s instructions (Qiagen).
Subsequently, amplification of the promoter regions
(FLT4: 337 bp; KDR:6 1 2b p )w a sp e r f o r m e du s i n gB S P
primers, specifically binding bisulfite converted DNA
(for primer sequence and PCR conditions see MSP sec-
tion). Resulting PCR products were purified, cloned into
the pGEM-TEasy vector (Prom e g a ,M a d i s o n ,W I ,U S A )
and sequenced. Sequences were evaluated using BiQ
Analyzer (http://biq-analyzer.bioinf.mpi-sb.mpg.de) and
had to conform to at least 90% bisulfite conversion rate.
In addition, identical clones were excluded from the
analysis.
Gene expression analyses
Quantitative PCR was performed on a 7500 Applied
Biosystems (Darmstadt, Germany) real-time PCR system
using the manufacturer’s protocol. RNA was prepared
using the RNeasy Mini kit (Qiagen). This kit includes a
DNase digestion step to avoid false positives resulting
from contaminating genomic DNA. For mRNA quantifi-
cation, reverse transcription was performed using the
SuperScript II reverse transcriptase kit (Invitrogen,
Karlsruhe, Germany). TaqMan probes (Applied Biosys-
tems) were used to quantify human FLT4 (Hs 01047677
m1) and KDR (Hs 00911700 m1) expression levels with
TATA box binding protein (TBP) as endogenous control.
For interferon gamma inducible protein 10 (IP-10)a n d
tumor necrosis factor alpha (TNFa), SYTO-82 (Molecu-
lar Probes, Leiden, Netherlands) was used as fluorescent
dye, ImmoMix (Biline, Luckenwalde, Germany) as PCR
master mix, and ribosomal protein S9 (RPS9)a se n d o -
genous control. The following primers were used: TNFa
exon 2 fwd 5’-CCC CAG GGA CCT CTC TCT AA-3’,
TNFa exon 3 rev 5’-TGG GCT ACA GGC TTG TCA
CT-3’; IP-10 exon 1 fwd 5’-GCC ATT CTG ATT TGC
TGC CTT A -3’, IP-10 exon 2 rev 5’-TGA TGC AGG
TAC AGC GTA CAG-3’; RPS9 exon 2 fwd 5’-GGG
AAG CGG AGC CAA CAT G-3’, RPS9 exon 3 rev 5’-
GTT TGT TCC GGA GCC CAT ACT-3’.R e l a t i v e
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method.
[
3H]-Thymidine uptake
Assays of [
3H]-thymidine incorporation were executed
as follows: 1.25 × 10
4 cells (in 100 μl) were seeded in
triplicate in 96-well flat-bottom microtiter cell culture
plates. Inhibitors were added as 2x concentrated solu-
tion in a 100 μl volume. For the last 3 h of the incuba-
tion period, 1 μCi [
3H]-thymidine (Hartmann Analytic,
Braunschweig, Germany) was added to each well.
Western blot analysis, antibodies, reagents
Samples were prepared as described previously [17]. Anti
FLT4, ERK and pERK antibodies were purchased from
Santa Cruz (Heidelberg, Germany). Anti IB, pIB, KDR,
p38 MAPK and pp38 MAPK antisera were obtained from
Cell Signalling (New England Biolabs, Frankfurt, Ger-
many). The anti GAPDH monoclonal antibody (mAb)
was purchased from Abcam (Cambridge, UK). Specific
bands on nitrocellulose membranes were visualized with
the biotin/streptavidin-horseradish peroxidase system
(Amersham, Freiburg, Germany) in combination with the
“Renaissance Western Blot Chemoluminescence
Reagent” protocol (Perkin Elmer, Waltham, MA, USA).
Synthetic macrophage activating factor of 2 kDa molecu-
lar mass (MALP-2) was a gift from P. Mühlradt to H.
Weich. The preparation was free of endotoxin.
Analysis of FLT4 and KDR protein expression by flow
cytometry
For detection of CD31 (Becton Dickinson Biosciences,
Heidelberg, Germany), FLT4 (R&D Systems, Wiesbaden,
Germany), KDR (Reliatech, Wolfenbüttel, Germany) and
podoplanin (Reliatech) on the cell surface, cells were
washed and incubated with the mouse mAb or with the
isotope-matched control mouse immunoglobulin (BD
Biosciences) for 30 min at 4°C. Subsequently, cells were
treated with FITC conjugated anti-mouse secondary Ab
(Biozol, Eching, Germany) and propidium iodide.
Labeled cells were analyzed on a FACSCalibur (BD Bios-
ciences) using CellQuest Pro software.
Treatment with DNA demethylating agent 5-Aza-2’-
deoxycytidine (5-Aza-dC)
5-Aza-dC (Sigma Aldrich, Taufkirchen, Germany) dis-
solved in DMSO was used to verify the effect of methy-
lation on expression of FLT4 and KDR.C e l l sw e r e
seeded at a cell density of 5 × 10
5 cells/ml, 5-Aza-dC
was added at a final concentration of 5 μM. Control
cells were treated with 0.05% DMSO. After 2 d, half of
the medium was replenished with medium with/without
5-Aza-dC (5 μM). After 3 d, cells were harvested to pre-
pare RNA and protein.
Results and Discussion
Expression of KDR and FLT4 in leukemia and lymphoma
cell lines
The VEGF-Rs KDR (VEGF-R2) and FLT4 (VEGF-R3) are
not only expressed on blood endothelial and lymphen-
dothelial cells, but also on solid tumors and leukemias.
Leukemia-derived VEGFs may induce the growth of leu-
kemic cells in an autocrine or paracrine fashion
[7,10,18,19]. The promoters of VEGF-Rs and their
ligands contain CpG islands, regulatory regions that are
typically methylated in epigenetically silenced genes
[14]. Recent reports show that expression of FLT1 and
KDR are controlled by promoter methylation [14,15].
However, only a limited number of leukemia and lym-
phoma cell lines have been tested for VEGF-R expres-
sion and promoter methylation hitherto.
To find model systems for VEGF-R regulation, we
tested some ninety leukemia and lymphoma cell lines
for KDR and FLT4 mRNA expression. Both genes were
regularly expressed in leukemia but not in lymphoma
cell lines: 10/62 (16%) cell lines from various leukemic
entities expressed KDR, 27/65 (42%) expressed FLT4
(Table 1). In contrast, 0/30 lymphoma cell lines
expressed KDR, and only 1/30 (3%) expressed FLT4
(Table 1). Cell lines with high VEGF-R transcript levels
expressed also the corresponding proteins: cell lines
CMK, HEL and MEG-01 expressed KDR, whereas cell
l i n e sH E L ,M H H - C A L L 2 ,O C I - A M L 1a n dS U P - B 1 5
were FLT4 positive (Figure 1, Table 2).
OCI-AML1: a model system for VEGF-C induced cell
signaling
Cytokine-dependent cell lines have often and successfully
been used as model systems for signal transduction stu-
dies. In contrast to primary cells, no contaminating cell
fraction effects “false” signals in cell lines, and in contrast
to cytokine-independently growing cell lines, cytokine
starvation silences the relevant enzymes in cytokine-
dependent cell lines. We chose cell line OCI-AML1 as
this was the only cytokine dependent, FLT4 positive cell
line tested (Table 2). The cytokine response profile of
this cell line has been published previously [20]. Cell line
OCI-AML1 did not show a proliferative response on
VEGF-C (data not shown). However, short-term (5 min)
stimulation with VEGF-C induced phosphorylation of
ERK1/2 (Figure 2). Preincubation with the FLT4 inhibitor
MAZ51 inhibited this effect, confirming the specificity of
the VEGF-C induced EKR1/2 activation (Figure 2).
ERK1/2 phosphorylation was tested because the p42/44
MAPK pathway is a known FLT4 target [21,22]. The
results of cell signaling experiments shown in Figure 2
confirm that cell line OCI-AML1 is a model system for
FLT4 signaling, expecially as KDR, the second receptor
for VEGF-C is not expressed in this cell line (Table 2).
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To test whether KDR is epigenetically regulated, we per-
formed bisulfite sequencing of KDR negative and posi-
tive cell lines and of primary endothelial cells. The KDR
negative cell line DOHH-2 had a highly methylated
KDR promoter, the KDR positive cell line HEL was
nearly unmethylated (Figure 3). Largely unmethylated
were also HDMECs and HUVECs, both expressing KDR
(Figure 3). To assess the KDR methylation status for a
larger number of cell lines, we performed methylation-
specific PCR (MSP), a technique less costly and labor-
ious than bisulfite sequencing. The majority of KDR
negative cell lines were methylated, KDR positive
HUVECs were unmethylated (Figure 4). However, even
HDMECs were U-and M-PCR positive although they
expressed high KDR levels and although only a small
minority of clones were methylated according to
sequencing analysis (Figures 3 and 4). Apparently, a low
proportion of methylated CpGs was sufficient to yield
signals in the M-PCR. The same was true for U-PCR:
the KDR negative cell line DOHH-2 - highly methylated
according to the results of bisulfite sequencing–showed
signals in M- and in U-PCR (Figure 3, Table 2).
In spite of the high sensitivity–a certain drawback of
the PCR-based MSP technique–the accuracy of KDR M-
PCR was 88% supporting the notion that KDR expres-
sion is regulated by DNA methylation (Table 2).
FLT4: promoter methylation and gene expression
Bisulfite sequencing and BSP analysis were also per-
formed to analyze the methylation status of FLT4 in cell
lines, HUVECs and HDMECs. Results of bisulfite
sequencing showed that FLT4 was largely methylated in
the FLT4 negative cell line EM-2 and unmethylated in
the FLT4 positive cell line SUP-B15 as it was in
HUVECs and HDMECs (Figure 5). MSP analysis con-
firmed that FLT4 exhibited the inverse correlation
Table 1 VEGF-R mRNA expression in leukemia and
lymphoma cell lines
KDR
+++ ++ + (+) - ∑
AML 0 2 0 3 16 21
pre-B ALL 0 0 0 1 10 11
T-ALL 0 0 0 2 9 11
NK 0 0 0 0 5 5
CML 1 0 0 1 12 14
HL 0 0 0 0 5 5
ALCL 0 0 0 0 5 5
BL 0 0 0 0 5 5
DLBCL 0 0 0 0 5 5
FL 0 0 0 0 5 5
MCL 0 0 0 0 5 5
∑ 1 2 0 7 82 92
FLT4
+++ ++ + (+) - ∑
AML 0 2 4 3 14 23
pre-B ALL 0 3 1 3 4 11
T-ALL 0 0 2 4 5 11
NK 0 0 0 0 5 5
CML 0 1 1 3 10 15
HL 0 0 0 1 4 5
ALCL 0 0 0 0 5 5
BL 0 0 0 0 5 5
DLBCL 0 0 0 0 5 5
FL 0 0 0 0 5 5
MCL 0 0 0 0 5 5
∑ 068 1 4 6 7 9 5
KDR and FLT4 mRNA expression levels were determined by quantitative real-
time PCR. TBP expression was used as endogenous control and cell lines CMK
(KDR) and HEL (FLT4) were used for normalization. Relative quantification: +++
≥ 5; ++ ≥ 1; + ≥ 0.2; (+) ≥ 0.04;- < 0.04. AML, acute myeloid leukemia; ALL,
acute lymphoblastic leukemia; NK, natural killer leukemia; CML, chronic
myeloid leukemia; HL, Hodgkin lymphoma; ALCL, anaplastic large cell
lymphoma; BL, Burkitt lymphoma; DLBCL, diffuse large B cell lymphoma; FL,
follicular lymphoma, MCL, mantle cell lymphoma
Figure 1 KDR and FLT4 in HDMECs, HUVECs and leukemia cell
lines. KDR and FLT4 mRNA expression levels were determined by
quantitative real-time PCR and indicated underneath the cell line
name. TBP expression was used as endogenous control and cell
lines CMK (KDR) and HEL (FLT4) were used for normalization. KDR
protein expression levels–determined by Western blot analysis–are
higher in HDMECs and HUVECs than in positive cell lines (note 1:10
lysate dilution in primary cells). FLT4 protein expression is higher in
HDMECs than in HUVECs (note 1:10 lysate dilution in HDMECs) and
in positive cell lines. Protein expression corresponds to mRNA
expression pattern.
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is indicative for epigenetic regulation (Figure 4, Table 2).
However, the accuracy of FLT4 M-PCR (80%) was lower
than for KDR M-PCR (88%). Of note was also that TF-1
cells did not express FLT4 although the promoter was
unmethylated (Table 2). These data suggested that regu-
latory mechanisms other than DNA methylation are
also important for the regulation of FLT4.
Effect of DNA demethylating agent 5-Aza-dC on
expression of KDR and FLT4
To test whether KDR and FLT4 were silenced by pro-
moter methylation, we treated methylated and unmethy-
lated cell lines with the DNA demethylating agent 5-
Aza-dC. In 4/5 KDR-negative cell lines, expression of
KDR was induced by DNA demethylation (Table 3).
FLT4 expression was upregulated in 4/4 negative cell
lines (Table 3). KDR and FLT4 expression in positive
cell lines were not affected (Table 3). Although these
results confirmed that promoter methylation plays a
role for the regulation of these VEGF-Rs,w ea l s on o t e d
substantial differences in the levels of 5-Aza-dC-trig-
gered gene induction between different cell lines (Table
3). Furthermore, even in the most sensitive cell lines
(HL-60 for KDR induction, EM-2 for FLT4 induction),
demethylation did not induce mRNA expression that
would translate into protein levels detectable by Wes-
tern blot analysis (data not shown). These results sug-
gest that other mechanisms than DNA methylation are
also involved in the regulation of KDR and FLT4.
Besides DNA methylation, also histone modifications
are epigenetic mechanisms that affect the expression of
individual genes. Just to mention two examples, acety-
lated histone H3 (at lysine 9 and 14) is a marker for
gene activation [23], tri-methylation of histone H3 lysine
27 stands for gene suppression [24]. Furthermore, epige-
netic modifications can influence each other: methylated
CpGs in a promoter region can be targeted by proteins
that interact with histone deacetylases. The consequence
is an inactive chromatin status and transcriptional
repression [25,26].
Table 2 Promoter methylation status and expression
levels of KDR and FLT4
KDR FLT4
MSP mRNA protein MSP mRNA protein
697 M 0.08 neg M/U 0 neg
ALL-SIL M 0 neg U 0.3 neg
AP-1060 M/U 0 n.d. M/U 0 n.d.
BV-173 M 0 neg U 1.4 pos
CMK M/U 1 pos M 0.1 neg
DOHH-2 M/U 0 neg M/U 0 neg
EM-2 M/U 0 neg M 0 neg
HANK-1 M 0 neg M 0 neg
HEL U 2.6 pos U 1 pos
HL-60 M 0 neg M 0.1 neg
JURL-MK1 U 0.15 n.d. n.d. n.d. n.d.
L-82 M 0 n.d. M 0 n.d.
LOUCY n.d. 0.13 neg M/U 0 neg
M-07e M/U 0.03 neg U 0.1 neg
MEG-01 U 5.8 pos U 0.2 pos
MEGAL M 0 neg M/U 0.3 neg
MHH-CALL2 M/U 0 neg U 1.1 pos
MHH-TALL1 M 0.08 n.d. n.d. n.d. n.d.
MOLT-4 M 0 n.d. M/U 0 n.d.
MUTZ-3 n.d. n.d. n.d. U 0.6 neg
MUTZ-8 n.d. n.d. n.d. M/U 0.3 neg
NK-92 M 0 neg M/U 0 neg
OCI-AML1 M/U 0 neg M/U 1.3 pos
SC-1 M 0 n.d. M 0 n.d.
SKNO-1 U 0.08 neg n.d. n.d. n.d.
SUP-B15 M 0 neg U 1.6 pos
TF-1 U 0.1 pos U 0 neg
THP-1 M/U 0 n.d. M/U 0 n.d.
KDR and FLT4 methylation was determined by MSP. M, positive in M-PCR; U,
positive in U-PCR, M/U positive in M- and in U-PCR; n.d., not done. VEGF-R
mRNA expression levels were determined by quantitative real-time PCR. Cell
lines CMK (KDR) and HEL (FLT4) were used for normalization (set to 1). Protein
expression was done by Western blot analysis. The accuracy of KDR M-PCR
(mRNA positivity > 0.1) is 88%, the accuracy of FLT4 M-PCR (mRNA positivity >
0.1) is 80%
Figure 2 Phosphorylation level of ERK1/2 in VEGF-C responsive
OCI-AML1 cells. The cytokine-responsive cell line OCI-AML1 was
cytokine-starved for 18 h, then stimulated for 5 min with VEGF-C.
Pretreatment with the FLT4 inhibitor MAZ51 (20 μM, 1 h) prevented
VEGF-C induced ERK1/2 phosphorylation as shown by Western blot
analysis.
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sence or absence of trans-acting factors may govern the
expression of KDR and FLT4. Thus, it has been shown
that transcription factor binding sites (Sp1, AP-2 and
NFB) are essential for the base-line activity of the KDR
promoter [27]. Here, we set out to find whether NFB
also plays a role for the expression of FLT4.
Influence of transactivating factors
During inflammation, new lymphatic vessels are formed.
NF-B is a key mediator of inflammatory processes and
has recently been identified as inducer of FLT4 on lym-
phatic endothelial cells [13]. To test whether NF-B
contributes to FLT4 expression in leukemic cells, we sti-
mulated the FLT4 negative cell line EM-2 and the FLT4
positive cell line OCI-AML1 with synthetic MALP-2.
MALP-2 binds to toll-like receptors-2 and -6 [28].
MALP-2 triggers the NF-B pathway [29] which leads
to the expression of NF-B targets like TNFa [30].
Accordingly, MALP-2 (100 ng/ml, 7 min) induced
phosphorylation and degradation of the NF-B inhibitor
IB and stimulated phosphorylation of p38 in cell lines
E M - 2a n dO C I - A M L 1( F i g u r e6 ) .M A L P - 2( 1 0 0n g / m l ,
1 h) triggered expression of the NK-Bt a r g e t sTNFa
(80× in EM-2, 1000× in OCI-AML1) and IP-10 (600× in
EM-2, > 1000× in OCI-AML1) in both cell lines. How-
ever, the expression of FLT4 was not affected, neither in
the FLT4 positive cell line OCI-AML1 nor in the FLT4
negative (methylated) cell line EM-2. MALP-2 did also
not increase the FLT4 stimulating effect of 5-Aza-dC on
EM-2 cells (data not shown). Thus, our results do not
support the view that NF-B is a transactivator of FLT4.
We observed a 10-fold increase in KDR in cell lines
OCI-AML1 and EM-2 (the latter pretreated with 5-Aza-
dC). However, as the level reached after stimulation was
still extremely low, it appears unlikey that NF-Bi sa n
important regulator for KDR either.
Figure 3 Bisulfite sequencing of the KDR promoter. A CpG island is located between -1231 and 1125 relative to the ATG codon of KDR. The
3’ part of the KDR promoter region and exon 1 (612 bp, 53 CpG sites) were sequenced after bisulfite conversion of DNA from cell lines DOHH-2
(KDR negative) and HEL (KDR positive) as well as from HDMECs and HUVECs. Each line depicts a sequenced clone representing the methylation
status of an individual allele. CpGs are represented as open dots (if unmethylated) or filled dots (if methylated). Results of qRT-PCR and
methylation specific PCR (MSP) are shown on the left hand side. M: signal in M-PCR; U: signal in U-PCR.
Figure 4 Methylation status of KDR and FLT4 in cell lines and
primary cells. The methylation status of KDR and FLT4 in leukemia
cell lines and in HDMECs and HUVECs was analyzed by MSP after
bisulfite conversion of the DNA. Agarose gels of KDR and FLT4 M-
and U-PCR are shown. A complete list of results is shown in Table 2.
NTC, non template control.
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HDMECs, HUVECs and KDR positive leukemia cell
lines exhibited demethylated KDR promoters (Figure 3,
Table 2). However, mRNA and protein levels were dis-
tinctly higher in the primary cells than in the leukemia
cell lines (Figure 1). Results of Western blot analysis
were confirmed by flow cytometry (Figure 7). HDMECs
and HUVECs expressed the pan-endothelial marker
CD31 (Figure 7). HDMECs, primarily consisting of lym-
phatic endothelial cells, were also positive for the
Figure 5 Bisulfite sequencing of the FLT4 promoter. A CpG island is located between -1231 and 769 relative to the ATG codon of FLT4. Part
of the promoter region (337 bp, 20 CpG sites) was sequenced from cell lines EM-2 (FLT4 negative) and SUP-B15 (FLT4 positive) as well as from
HDEMCs and HUVECs. Each line depicts a sequenced clone representing the methylation status of an individual allele. CpGs are represented as
open dots (if unmethylated) or filled dots (if methylated). Results of qRT-PCR and methylation specific PCR (MSP) are shown on the left hand
side. M: signal in M-PCR; U: signal in U-PCR.
Table 3 Effect of 5-Aza-dC on expression of KDR and
FLT4
KDR FLT4
mRNA induced by Aza mRNA induced by Aza
CMK pos - pos -
DOHH-2 neg + neg ++
EM-2 neg (+) neg +++
HL-60 neg +++ pos -
L-82 neg - neg +
SC-1 neg ++ neg +
Induction of KDR and FLT4 by 5-Aza-dC (5 μM, 3 d) when compared to
untreated control cells: - < 2.5-fold; (+) > 2.5-fold; + > 10-fold; ++ > 40-fold; +
++ > 160-fold. Expression levels were determined by qRT-PCR. TBP expression
was used as endogenous control, DMSO (0.05%) treated cells were used for
normalization
Figure 6 Degradation of IB and phosphorylation of p38MAPK
in MALP-2 responsive cell lines. Cell lines EM-2 (FLT4 negative)
and OCI-AML1 (FLT4 positive) were stimulated with MALP-2 (100
ng/ml). The NF-B inhibitor IB was phosphorylated (7 min) and
degraded (7 min, 21 min) in both cell lines. Likewise, rapid
phosphorylation of p38 MAPK was observed in both cell lines by
Western blot analysis. GAPDH is shown as loading control.
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Page 7 of 10lymphatic vessel marker podoplanin, HUVECs were
podoplanin negative (Figure 7). Both types of primary
cells expressed much higher levels of KDR than KDR-
positive cell lines (Figure 1). Also FLT4 expression levels
varied greatly from one cell type to the other: FLT4
expression of HUVECs was comparable to those of
FLT4 positive cell lines, while HDMECs showed much
higher FLT4 expression levels (Figures 1 and 7). These
results are in line with our data of MSP analyses and 5-
Aza-dC experiments suggesting that DNA methylation
Figure 7 Expression of KDR and FLT4 on HDMECs and HUVECs. Flow cytometry analysis for KDR, FLT4, the lymphatic vessel marker
podoplanin and the panendothelial marker CD31. Note that HDMECs and HUVECs show comparable KDR expression levels, while FLT4 is
stronger in lymphatic vessel cells (HDMECs) than in blood vessel cells (HUCECs). The non-filled peak shows the corresponding isotype control.
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Page 8 of 10is not the only mechanism that controls KDR and FLT4
gene expression.
Conclusions
Our data obtained from primary endothelial cells and
from leukemia/lymphoma cell lines show that KDR and
FLT4 are epigenetically regulated genes. Both genes can
be silenced by methylation. However, if the promoters
are unmethylated, other factors are responsible for the
extent of KDR and FLT4 expression. Furthermore, we
show that the KDR negative/FLT4 positive cell line
OCI-AML1 is a model system for FLT4 signal transduc-
tion studies.
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